Posttransplantation malignancy in a patient presenting with weight loss and changed bowel habits: a case report

[1]  B. Kahan,et al.  Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies , 2005, Transplantation.

[2]  P. Karran,et al.  Azathioprine and UVA Light Generate Mutagenic Oxidative DNA Damage , 2005, Science.

[3]  C. Ponticelli,et al.  Gastrointestinal complications in renal transplant recipients , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[4]  L. Gesualdo,et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.

[5]  H. Goldschmidt,et al.  Malignancy in renal transplantation. , 2004, Journal of the American Society of Nephrology : JASN.

[6]  Hua Yang,et al.  Tacrolimus enhances transforming growth factor-&bgr;1 expression and promotes tumor progression , 2003, Transplantation.

[7]  F. Luan,et al.  Rapamycin is an effective inhibitor of human renal cancer metastasis. , 2003, Kidney international.

[8]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[9]  M. Lagman,et al.  Cyclosporine induces cancer progression by a cell-autonomous mechanism , 1999, Nature.

[10]  B. Dréno,et al.  Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens , 1998, The Lancet.

[11]  E. Will,et al.  Risk of neoplasia in renal transplant patients , 1995, The Lancet.

[12]  Eero Pukkala,et al.  Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.

[13]  A. Sheil,et al.  De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. , 1993, Transplantation proceedings.

[14]  W. Seaman,et al.  Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. , 1987, Journal of immunology.